KOSDAQBiotech & Pharma0082N0

Kanaph Therapeutics

₩8,150▼ 0.37%2026-11-18 close
Market Cap
₩108.4B
Turnover
₩200M
Volume
30K
Shares out.
13.3M
PER
—
PBR
—
EPS
—
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Technology-transfer biotech; clinical data is the key test

Kanaph Therapeutics has built a sizable technology-transfer track record, yet it has posted an operating loss in each of the three quarters from Q1 to Q3 2026, making human clinical data and a global licensing deal the next milestones to watch.

  1. 1

    Revenue rose 30.8% to KRW 5.56 billion in 2025, but the company still posted an operating loss of KRW 4.27 billion.

  2. 2

    The net loss attributable to controlling shareholders widened to KRW 35.6 billion in 2025 from KRW 28.3 billion in 2024.

  3. 3

    Q3 2026 revenue fell 74.3% from the prior quarter to KRW 19.28 million, while the operating loss narrowed to KRW 3.55 billion.

  4. 4

    Most business revenue comes from technology transfers; the 2024 mix was 82.4% technology transfer and 17.6% research services.

  5. 5

    The company has set a target of at least one new clinical entry or technology deal every year and a return to profitability in 2028.

02

Business structure

Kanaph Therapeutics, founded in February 2019, is a drug developer that uses human genome analysis to find disease targets and then applies a suitable modality, such as bispecific antibodies, synthetic drugs or antibody-drug conjugates (ADCs).

Its model licenses candidates to Korean pharmaceutical companies at the preclinical stage, runs early clinical work with partners, and then seeks global licensing with the data it has generated.

Based on an IPO research report from Eugene Investment & Securities, the 2024 revenue mix was 82.4% technology transfer and 17.6% research services.

Cumulative licensing deal value, excluding royalties, reached KRW 774.8 billion, and upfront payments received totaled about KRW 15.9 billion as of end-2025, according to company briefing material. Partners include several Korean pharmaceutical companies, among them Yuhan, GC Biopharma and Lotte Biologics.

The core pipeline comprises KNP-502, an oral oncology drug co-developed with a partner and now in Phase 1; KNP-301, a bispecific antibody for wet age-related macular degeneration at the nonclinical stage; KNP-701, a bispecific ADC developed with GC Biopharma that is still preclinical; and KNP-504, an SOS1 inhibitor licensed to Yuhan.

In February 2026 the company said it targets clinical entry for KNP-504 in 2026. The company itself cites the lack of human clinical data and limited global licensing experience as weaknesses.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3———
2025Q4———
2026Q1₩78,157,037-₩5.4B−6937.1%
2026Q2₩74,959,414-₩4.7B−6265.3%
2026Q3₩19,277,997-₩3.6B−18439.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩4.3B-₩4.7B-₩28.3B−111.1%—−125.8%
2025₩5.6B-₩4.3B-₩35.6B−76.8%−287.3%24.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-11

04

Earnings analysis

On an annual basis, revenue rose 30.8% from KRW 4.25 billion in 2024 to KRW 5.56 billion in 2025. Over the same period the operating loss narrowed from KRW 4.72 billion to KRW 4.27 billion, and the operating margin improved from -111.1% to -76.8%.

Operating cash flow moved the other way, from -KRW 3.23 billion to -KRW 7.17 billion, so the cash burn widened. The net loss attributable to controlling shareholders grew from KRW 28.3 billion in 2024 to KRW 35.6 billion in 2025, while the net loss including non-controlling interests rose by the same amounts.

The net loss is about eight times the operating loss, which suggests non-operating items weighed heavily on the bottom line. Press reports state that the company posted a net profit of KRW 3.8 billion in 2022 before turning to a loss the following year.

At the end of 2025, total equity stood at KRW 12.4 billion, all of it attributable to controlling shareholders, and total liabilities were KRW 3.08 billion. The debt-to-equity ratio went from -125.8% in 2024 to 24.9% in 2025, and the negative 2024 figure points to a period when total equity was negative.

Quarterly revenue was KRW 78.16 million in Q1 2026, KRW 74.96 million in Q2 (down 4.1% from the prior quarter) and KRW 19.28 million in Q3 (down 74.3%), so revenue has declined for two consecutive quarters after the Q1 peak.

The operating loss was KRW 5.42 billion in Q1, KRW 4.7 billion in Q2 and KRW 3.55 billion in Q3, a steady narrowing, and the net loss attributable to controlling shareholders followed the same path at KRW 5.32 billion, KRW 4.34 billion and KRW 3.22 billion.

Because most revenue comes from technology transfers, quarterly revenue can swing sharply depending on when deal payments are recognized.

05

Industry analysis

Assessments of Korean biotech investment sentiment in early 2026 were mixed. One outlet noted that the listing came with a major pharmaceutical company as a strategic investor despite a chilled biotech investment climate.

Another said attention was on whether the investment enthusiasm that built up from late 2025 would continue. Technology-special-listing biotechs are being judged on clinical data, and Kanaph positions its early-licensing model as a way of sharing development risk.

The company says using human genome data to select targets raises the probability of clinical success; that figure is the company's own claim.

In the ADC field, the company presented preclinical tolerability data for KNP-701 at World ADC San Diego in October 2026, and it says the dose tolerated is more than three times the level at which a competing ADC showed side effects such as weight loss. These are preclinical results with no human data yet.

The company has pointed to the commercialization path of leclaza, developed with Oscotec and Yuhan, as its benchmark. Analysts note that the company still lacks global licensing experience and human clinical data.

06

Outlook

For 2026, the company's stated clinical-entry target is KNP-504, according to its February 2026 briefing. KNP-502 is in Phase 1, and the company expects Phase 1 data as early as 2027.

For KNP-301, a wet age-related macular degeneration candidate, the company aims to sign a global licensing deal as early as 2027, although one report also said the company may run Phase 1 itself before licensing.

KNP-701 targets clinical entry in 2027, but completing remaining nonclinical work, including toxicity testing in monkeys, is seen as uncertain.

In a September 2026 interview, the chief executive described a strategy called Kanaph 2.0, under which the company raises the value of core assets through its own clinical work before pursuing larger licensing deals. Because that shifts more clinical spending onto the company, R&D costs could rise.

Proceeds from the 2026 listing are earmarked for development of core candidates such as KNP-101 and KNP-701, clinical trial supplies and toxicity studies.

The company has targeted a return to profit in 2028, but its registration filing states that if further development fails within the set period, additional milestone or royalty income may not arise. Whether that target is met depends on clinical results and deal execution.

07

Valuation

PER
—
PBR
—
ROE
-287.3%
EPS
—
BPS
—
Dividend per share
₩0

Kanaph Therapeutics has posted a net loss over the most recent four quarters, so its price-to-earnings ratio cannot be calculated. The company pays no dividend, so comparisons based on dividend yield do not apply.

Its market capitalization is well above total equity at the end of 2025, placing the stock in a range where the price carries a large premium to net asset value. One outlet observed that the company's valuation reflects future value more than current earnings.

The same report noted that the share price direction after listing is tied to interim Phase 1 results for KNP-502 and further global licensing outcomes. The operating margin improved from -111.1% to -76.8%, yet operating losses remain large relative to revenue.

Because the company's stated target for returning to profit is 2028, valuation comparisons will depend on how the income structure changes before then.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-11

08

Bull factors

Several pipeline assets near clinical stages

KNP-502 is in Phase 1, with data expected as early as 2027. The company said KNP-701 showed tolerability more than three times that of a competing ADC in October 2026 preclinical data. KNP-301 is targeted for a global licensing deal as early as 2027.

Large cumulative deal value and diversified partners

Cumulative licensing deal value, excluding royalties, is KRW 774.8 billion, with KRW 15.9 billion in upfront payments received. Partners include several Korean pharmaceutical companies such as Yuhan, GC Biopharma and Lotte Biologics.

In March 2026 the company said GC Biopharma exercised an ADC option, moving a preclinical asset into development.

Narrowing losses

The operating margin improved from -111.1% in 2024 to -76.8% in 2025. Operating losses narrowed over the three quarters of 2026, from KRW 5.42 billion to KRW 4.7 billion and then KRW 3.55 billion. The net loss attributable to controlling shareholders also shrank over the same quarters.

09

Bear factors

No human clinical data yet

The company has released preclinical data, but it has no human clinical data yet. Early Phase 1 licensing is seen as the variable that will determine the company's value. Completing remaining nonclinical work, including monkey toxicity studies, on schedule is also uncertain.

Revenue decline and volatility

Q2 2026 revenue fell 4.1% from the prior quarter, and Q3 revenue fell 74.3% to KRW 19.28 million. Revenue has declined for two consecutive quarters. Because most revenue comes from technology transfers, quarterly results can vary widely depending on deal timing.

Larger losses and cash burn

The net loss attributable to controlling shareholders widened to KRW 35.6 billion in 2025 from KRW 28.3 billion in 2024. Operating cash outflow reached -KRW 7.17 billion, larger than the prior year's -KRW 3.23 billion.

The net loss over the last four quarters, KRW 35.6 billion, exceeds total equity of KRW 12.4 billion at end-2025.

10

Risk factors

Clinical failure or delay

Most pipeline assets are early-stage, so their value will be hard to prove until clinical results arrive. The company's own registration filing states that milestone or royalty income may not arise if clinical programs do not proceed smoothly. A delay in clinical entry could also push back the 2028 target for returning to profit.

Funding needs and rising costs

Proceeds from the March 2026 listing are earmarked for development and clinical costs of core candidates. A larger share of self-run clinical work could raise R&D spending. Given that operating cash outflow widened, whether additional funding is needed could affect future plans.

Dependence on licensing deals

Most business revenue comes from technology transfers, so results depend heavily on the timing and terms of deals. Analysts note limited experience with global licensing. Deal terms could change depending on how partners' clinical programs progress.

11

What to watch next

  1. Late 2026

    Whether KNP-504 enters the clinic as targeted for 2026, a goal set at the February 2026 briefing and a gauge of pipeline expansion pace.

  2. Around late March 2027

    Filing of the 2026 annual report, covering the full-year operating loss, upfront payments from licensing and the company's explanation of its 2028 profitability target.

  3. Around mid-May 2027

    The Q1 2027 quarterly report, which will show whether the narrowing operating loss and the two-quarter revenue decline continue.

  4. During 2027

    Whether KNP-502 Phase 1 data is released, whether a KNP-301 global licensing deal is signed, and whether KNP-701 enters the clinic. These will indicate whether the company meets its target of at least one deal or clinical entry each year.

12

Overall view

Kanaph Therapeutics has built KRW 774.8 billion in cumulative licensing deal value through human genome-based target discovery and an early-licensing model, but its financials still show losses. Revenue rose 30.8% to KRW 5.56 billion in 2025, and the operating margin improved from -111.1% to -76.8%.

The net loss attributable to controlling shareholders widened to KRW 35.6 billion, and Q3 2026 revenue fell to KRW 19.28 million. On the positive side are the clinical-stage pipeline, large pharmaceutical partners and three consecutive quarters of narrowing operating losses.

On the negative side are the lack of human clinical data, heavy reliance on licensing income and a recent net loss larger than total equity. The company's 2028 profitability target depends on clinical results and deal execution.

The next checkpoints are the 2026 annual report, Q1 2027 results, KNP-502 Phase 1 data and whether the KNP-301 licensing deal is signed.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. thevc.kr
  2. biospectator.com
  3. dealsite.co.kr
  4. innoforest.co.kr
  5. medicaltimes.com
  6. hitnews.co.kr
  7. saramin.co.kr
  8. eugenefn.com
  9. kanaphtx.com
  10. hankyung.com
  11. biotimes.co.kr
  12. hitnews.co.kr
  13. etoday.co.kr
  14. news.nate.com
  15. m.news.nate.com
  16. m.news.nate.com
  17. m.news.nate.com
  18. ncbi.nlm.nih.gov

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis